Spots Global Cancer Trial Database for Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Official Title: A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM)

Study ID: NCT04489420

Conditions

Astrocytoma, Grade IV

Giant Cell Glioblastoma

Glioblastoma Multiforme

Cyclophosphamide

Immunosuppressive Agents

Immunologic Factors

Physiological Effects of Drugs

Molecular Mechanisms of Pharmacological Action

Antiviral Agents

Anti-infective Agents

Analgesics, Non-narcotic

Analgesics

Sensory System Agents

Peripheral Nervous System Agents

Interventions

CYNK001-IV

CYNK001-IT

Study Description

Brief Summary: This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.

Detailed Description: